Pretreatment expression of miR-191a may predict response to the induction chemotherapy based on cytarabine in acute myeloid leukemia patients – a single-center pilotal study

Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recogn...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 20; no. 6; p. e0324320
Main Authors Szymczyk, Agnieszka, Chocholska, Sylwia, Radko, Katarzyna, Hus, Marek, Podhorecka, Monika
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 24.06.2025
Public Library of Science (PLoS)
Subjects
Acute myeloid leukemia
Adult
Aged
Analysis
Antimetabolites, Antineoplastic - therapeutic use
Biology and life sciences
Bone marrow
Chemotherapy
Chromosomes
Cytarabine
Cytarabine - therapeutic use
Disease
Epigenetics
Female
fms-Like Tyrosine Kinase 3 - genetics
Gene Expression Regulation, Leukemic - drug effects
Genes
Genetic disorders
Health aspects
Humans
Induction Chemotherapy
Induction therapy
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemogenesis
Male
Medical prognosis
Medicine and Health Sciences
MicroRNA
MicroRNAs
MicroRNAs - genetics
MicroRNAs - metabolism
Middle Aged
miRNA
Morphology
Mutation
Nucleophosmin
Oncology
Patients
Pilot Projects
Prognosis
Remission (Medicine)
Risk factors
Statistical analysis
Stem cell transplantation
Testing
Treatment Outcome
Variables
Young Adult
Poland
United States > US
Online AccessGet full text

Cover

Abstract Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recognized to play an important role in pathological leukemogenesis. This study is aimed to analyze the possible role of micro RNAs as a markers predicting the outcome to induction chemotherapy based on cytarabine. The expression of miR-34a, miR-191, miR-199a and miR-199b in previously separated bone marrow cells was assessed at the moment of diagnosis in 44 AML patients with use of qRQ-PCR technique. Assessment of response to induction therapy was based on criteria for response to treatment proposed by European LeukemiaNet (ELN). Only the expression level of miR-191a out of all analyzed microRNAs was significantly associated with the induction chemotherapy response. We detected also significantly higher expression of miR-191 in FLT3-ITD negative group in comparison to FLT3-ITD positive subjects. For miR-34a, miR-199a and miR-199b, no relationship was found between their expression and FLT3-ITD, NPM1 and CEBPA mutations. It was also shown that in the group of patients with low miR-191 expression, the number of myeloblasts was higher (p < 0.05). These results may prove an important role of miR-191a expression as a predictor of response to the induction chemotherapy based on cytarabine, even in cases when other risk factors are absent.
AbstractList Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recognized to play an important role in pathological leukemogenesis. This study is aimed to analyze the possible role of micro RNAs as a markers predicting the outcome to induction chemotherapy based on cytarabine. The expression of miR-34a, miR-191, miR-199a and miR-199b in previously separated bone marrow cells was assessed at the moment of diagnosis in 44 AML patients with use of qRQ-PCR technique. Assessment of response to induction therapy was based on criteria for response to treatment proposed by European LeukemiaNet (ELN). Only the expression level of miR-191a out of all analyzed microRNAs was significantly associated with the induction chemotherapy response. We detected also significantly higher expression of miR-191 in FLT3-ITD negative group in comparison to FLT3-ITD positive subjects. For miR-34a, miR-199a and miR-199b, no relationship was found between their expression and FLT3-ITD, NPM1 and CEBPA mutations. It was also shown that in the group of patients with low miR-191 expression, the number of myeloblasts was higher (p < 0.05). These results may prove an important role of miR-191a expression as a predictor of response to the induction chemotherapy based on cytarabine, even in cases when other risk factors are absent.
Background Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recognized to play an important role in pathological leukemogenesis. This study is aimed to analyze the possible role of micro RNAs as a markers predicting the outcome to induction chemotherapy based on cytarabine. Materials and methods The expression of miR-34a, miR-191, miR-199a and miR-199b in previously separated bone marrow cells was assessed at the moment of diagnosis in 44 AML patients with use of qRQ-PCR technique. Assessment of response to induction therapy was based on criteria for response to treatment proposed by European LeukemiaNet (ELN). Results Only the expression level of miR-191a out of all analyzed microRNAs was significantly associated with the induction chemotherapy response. We detected also significantly higher expression of miR-191 in FLT3-ITD negative group in comparison to FLT3-ITD positive subjects. For miR-34a, miR-199a and miR-199b, no relationship was found between their expression and FLT3-ITD , NPM1 and CEBPA mutations. It was also shown that in the group of patients with low miR-191 expression, the number of myeloblasts was higher (p < 0.05). Conclusions These results may prove an important role of miR-191a expression as a predictor of response to the induction chemotherapy based on cytarabine, even in cases when other risk factors are absent.
BackgroundAcute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recognized to play an important role in pathological leukemogenesis. This study is aimed to analyze the possible role of micro RNAs as a markers predicting the outcome to induction chemotherapy based on cytarabine.Materials and methodsThe expression of miR-34a, miR-191, miR-199a and miR-199b in previously separated bone marrow cells was assessed at the moment of diagnosis in 44 AML patients with use of qRQ-PCR technique. Assessment of response to induction therapy was based on criteria for response to treatment proposed by European LeukemiaNet (ELN).ResultsOnly the expression level of miR-191a out of all analyzed microRNAs was significantly associated with the induction chemotherapy response. We detected also significantly higher expression of miR-191 in FLT3-ITD negative group in comparison to FLT3-ITD positive subjects. For miR-34a, miR-199a and miR-199b, no relationship was found between their expression and FLT3-ITD, NPM1 and CEBPA mutations. It was also shown that in the group of patients with low miR-191 expression, the number of myeloblasts was higher (p < 0.05).ConclusionsThese results may prove an important role of miR-191a expression as a predictor of response to the induction chemotherapy based on cytarabine, even in cases when other risk factors are absent.
Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recognized to play an important role in pathological leukemogenesis. This study is aimed to analyze the possible role of micro RNAs as a markers predicting the outcome to induction chemotherapy based on cytarabine. The expression of miR-34a, miR-191, miR-199a and miR-199b in previously separated bone marrow cells was assessed at the moment of diagnosis in 44 AML patients with use of qRQ-PCR technique. Assessment of response to induction therapy was based on criteria for response to treatment proposed by European LeukemiaNet (ELN). Only the expression level of miR-191a out of all analyzed microRNAs was significantly associated with the induction chemotherapy response. We detected also significantly higher expression of miR-191 in FLT3-ITD negative group in comparison to FLT3-ITD positive subjects. For miR-34a, miR-199a and miR-199b, no relationship was found between their expression and FLT3-ITD, NPM1 and CEBPA mutations. It was also shown that in the group of patients with low miR-191 expression, the number of myeloblasts was higher (p < 0.05). These results may prove an important role of miR-191a expression as a predictor of response to the induction chemotherapy based on cytarabine, even in cases when other risk factors are absent.
Background Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recognized to play an important role in pathological leukemogenesis. This study is aimed to analyze the possible role of micro RNAs as a markers predicting the outcome to induction chemotherapy based on cytarabine. Materials and methods The expression of miR-34a, miR-191, miR-199a and miR-199b in previously separated bone marrow cells was assessed at the moment of diagnosis in 44 AML patients with use of qRQ-PCR technique. Assessment of response to induction therapy was based on criteria for response to treatment proposed by European LeukemiaNet (ELN). Results Only the expression level of miR-191a out of all analyzed microRNAs was significantly associated with the induction chemotherapy response. We detected also significantly higher expression of miR-191 in FLT3-ITD negative group in comparison to FLT3-ITD positive subjects. For miR-34a, miR-199a and miR-199b, no relationship was found between their expression and FLT3-ITD, NPM1 and CEBPA mutations. It was also shown that in the group of patients with low miR-191 expression, the number of myeloblasts was higher (p < 0.05). Conclusions These results may prove an important role of miR-191a expression as a predictor of response to the induction chemotherapy based on cytarabine, even in cases when other risk factors are absent.
Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recognized to play an important role in pathological leukemogenesis. This study is aimed to analyze the possible role of micro RNAs as a markers predicting the outcome to induction chemotherapy based on cytarabine.BACKGROUNDAcute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent prognostic factors that are taken into account to determine prognosis and treatment. MicroRNAs are novel gene regulators, which have been recognized to play an important role in pathological leukemogenesis. This study is aimed to analyze the possible role of micro RNAs as a markers predicting the outcome to induction chemotherapy based on cytarabine.The expression of miR-34a, miR-191, miR-199a and miR-199b in previously separated bone marrow cells was assessed at the moment of diagnosis in 44 AML patients with use of qRQ-PCR technique. Assessment of response to induction therapy was based on criteria for response to treatment proposed by European LeukemiaNet (ELN).MATERIALS AND METHODSThe expression of miR-34a, miR-191, miR-199a and miR-199b in previously separated bone marrow cells was assessed at the moment of diagnosis in 44 AML patients with use of qRQ-PCR technique. Assessment of response to induction therapy was based on criteria for response to treatment proposed by European LeukemiaNet (ELN).Only the expression level of miR-191a out of all analyzed microRNAs was significantly associated with the induction chemotherapy response. We detected also significantly higher expression of miR-191 in FLT3-ITD negative group in comparison to FLT3-ITD positive subjects. For miR-34a, miR-199a and miR-199b, no relationship was found between their expression and FLT3-ITD, NPM1 and CEBPA mutations. It was also shown that in the group of patients with low miR-191 expression, the number of myeloblasts was higher (p < 0.05).RESULTSOnly the expression level of miR-191a out of all analyzed microRNAs was significantly associated with the induction chemotherapy response. We detected also significantly higher expression of miR-191 in FLT3-ITD negative group in comparison to FLT3-ITD positive subjects. For miR-34a, miR-199a and miR-199b, no relationship was found between their expression and FLT3-ITD, NPM1 and CEBPA mutations. It was also shown that in the group of patients with low miR-191 expression, the number of myeloblasts was higher (p < 0.05).These results may prove an important role of miR-191a expression as a predictor of response to the induction chemotherapy based on cytarabine, even in cases when other risk factors are absent.CONCLUSIONSThese results may prove an important role of miR-191a expression as a predictor of response to the induction chemotherapy based on cytarabine, even in cases when other risk factors are absent.
Audience Academic
Author Szymczyk, Agnieszka
Chocholska, Sylwia
Radko, Katarzyna
Hus, Marek
Podhorecka, Monika
AuthorAffiliation 1 Department of Hematology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland
European Institute of Oncology, ITALY
2 Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
AuthorAffiliation_xml – name: 2 Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
– name: European Institute of Oncology, ITALY
– name: 1 Department of Hematology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland
Author_xml – sequence: 1
  givenname: Agnieszka
  orcidid: 0000-0001-8347-7557
  surname: Szymczyk
  fullname: Szymczyk, Agnieszka
– sequence: 2
  givenname: Sylwia
  surname: Chocholska
  fullname: Chocholska, Sylwia
– sequence: 3
  givenname: Katarzyna
  surname: Radko
  fullname: Radko, Katarzyna
– sequence: 4
  givenname: Marek
  surname: Hus
  fullname: Hus, Marek
– sequence: 5
  givenname: Monika
  surname: Podhorecka
  fullname: Podhorecka, Monika
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40554554$$D View this record in MEDLINE/PubMed
BookMark eNqNk9tu1DAQhiNURA_wBggsISG42MVO7GxyhaqKQ6VKReVwa02c8a6LEwfbQd073oEH4Z14Ehx2W3VRL1AiJfrnm5nMH89htte7HrPsMaNzVizYq0s3-h7sfEjynBY5L3J6LztgdZHPypwWe7fe97PDEC4pFUVVlg-yfU6F4Ok-yH598Bg9QuywjwSvBo8hGNcTp0lnLmasZkA6WJMUaI2KJMVTx4AkOhJXSEzfjipOGWqFnUuSh2FNGgjYkkldR_DQmH5CCagxIunWaJ1picXxK3YGyADRpP6B_P7xkwAJpl9anKkkoSeDsS6CJSGO7fphdl-DDfho-zzKPr998-nk_ezs_N3pyfHZTJWcx1nJNQNdFguhaKMa0YjkD2ilWNUu2rKp1IIqXQsQFFWOVcNFrSkudKNELXReHGVPN3UH64Lceh1kkeeThYzXiTjdEK2DSzl404FfSwdG_hWcX0rw0SiLshCLsmZTC825whzKEqkWBTCum3Yx1Xq97TY2HbbT4B7sTtHdSG9Wcum-S5azqqzqIlV4sa3g3bcRQ5SdCQqthR7duPnwOq_qmib02T_o3eNtqSWkCUyvXWqspqLyuOIipzUvp7bzO6h0tem_qnQytUn6TsLLnYTERLyKSxhDkKcfL_6fPf-yyz6_xa4QbFwFZ8fpZIZd8Mltq288vl6JBPANoLwLwaO-QRiV0-Zd2yWnzZPbzSv-AFjvJE8
Cites_doi 10.1124/dmd.114.062844
10.1182/blood-2016-03-643544
10.1186/s40164-016-0033-6
10.1186/1745-6673-8-14
10.3390/genes10040319
10.1182/blood-2007-07-098749
10.1186/s12943-016-0518-2
10.1038/bcj.2016.50
10.1186/1746-1596-9-76
10.3389/fonc.2017.00255
10.1016/j.clml.2019.08.007
10.1016/S0268-960X(03)00040-7
10.1053/j.seminoncol.2008.04.007
10.1182/blood.2022016867
10.1371/journal.pone.0164587
10.1186/gm516
10.1038/nature11919
ContentType Journal Article
Copyright Copyright: © 2025 Szymczyk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
COPYRIGHT 2025 Public Library of Science
2025 Szymczyk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 Szymczyk et al 2025 Szymczyk et al
2025 Szymczyk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: Copyright: © 2025 Szymczyk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
– notice: COPYRIGHT 2025 Public Library of Science
– notice: 2025 Szymczyk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 Szymczyk et al 2025 Szymczyk et al
– notice: 2025 Szymczyk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QG
7QL
7QO
7RV
7SN
7SS
7T5
7TG
7TM
7U9
7X2
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M7N
M7P
M7S
NAPCQ
P5Z
P62
P64
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
PYCSY
RC3
7X8
5PM
DOA
DOI 10.1371/journal.pone.0324320
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Opposing Viewpoints (Gale in Context)
Gale In Context: Science
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Nursing & Allied Health Database
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
ProQuest Health & Medical Collection (NC LIVE)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Advanced Technologies & Aerospace Collection
Agricultural & Environmental Science Collection
ProQuest Central Essentials
Biological Science Database
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Materials Science Database (NC LIVE)
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
ProQuest Biological Science Collection
Agricultural Science Database
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Engineering Database
ProQuest Nursing & Allied Health Premium
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Materials Science Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
Environmental Science Collection
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Agricultural Science Database
Publicly Available Content Database
ProQuest Central Student
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Agricultural Science Database

MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
DocumentTitleAlternate Expression of miR-191a in acute myeloid leukemia patients
EISSN 1932-6203
ExternalDocumentID 3223866149
oai_doaj_org_article_357691459ff44ce2a66e0f53a14fbd79
PMC12186893
A845209463
40554554
10_1371_journal_pone_0324320
Genre Journal Article
GeographicLocations Poland
United States--US
GeographicLocations_xml – name: Poland
– name: United States--US
GrantInformation_xml – fundername: ;
  grantid: DS176
GroupedDBID ---
123
29O
2WC
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABIVO
ABJCF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAWUL
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
EMOBN
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IGS
IHR
IHW
INH
INR
IOV
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
O5R
O5S
OK1
OVT
P2P
P62
PATMY
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PTHSS
PV9
PYCSY
RNS
RPM
RZL
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
ADRAZ
BBORY
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
3V.
7QG
7QL
7QO
7SN
7SS
7T5
7TG
7TM
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
KL.
M7N
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c644t-64f1af6375c0bcb5b5243afcc18d7d6b8c70cf95a50ec2e8b459f0e7fbc595f23
IEDL.DBID M48
ISSN 1932-6203
IngestDate Sun Aug 31 00:07:57 EDT 2025
Wed Aug 27 01:16:13 EDT 2025
Thu Aug 21 18:26:29 EDT 2025
Fri Jul 11 16:59:16 EDT 2025
Fri Jul 25 09:18:50 EDT 2025
Wed Jul 16 16:52:51 EDT 2025
Tue Jul 15 03:51:16 EDT 2025
Thu Jul 10 08:47:05 EDT 2025
Thu Jul 10 08:47:07 EDT 2025
Tue Jul 15 02:10:19 EDT 2025
Fri Jun 27 02:12:37 EDT 2025
Tue Aug 05 12:00:33 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License Copyright: © 2025 Szymczyk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c644t-64f1af6375c0bcb5b5243afcc18d7d6b8c70cf95a50ec2e8b459f0e7fbc595f23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
ORCID 0000-0001-8347-7557
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0324320
PMID 40554554
PQID 3223866149
PQPubID 1436336
PageCount e0324320
ParticipantIDs plos_journals_3223866149
doaj_primary_oai_doaj_org_article_357691459ff44ce2a66e0f53a14fbd79
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12186893
proquest_miscellaneous_3223928990
proquest_journals_3223866149
gale_infotracmisc_A845209463
gale_infotracacademiconefile_A845209463
gale_incontextgauss_ISR_A845209463
gale_incontextgauss_IOV_A845209463
gale_healthsolutions_A845209463
pubmed_primary_40554554
crossref_primary_10_1371_journal_pone_0324320
PublicationCentury 2000
PublicationDate 20250624
PublicationDateYYYYMMDD 2025-06-24
PublicationDate_xml – month: 6
  year: 2025
  text: 20250624
  day: 24
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, CA USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2025
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References JK Rieger (pone.0324320.ref014) 2015; 43
J Zhao (pone.0324320.ref016) 2014; 9
X Liu (pone.0324320.ref018) 2020; 66
H Döhner (pone.0324320.ref007) 2022; 140
C-H Yeh (pone.0324320.ref009) 2016; 15
I Polychronakis (pone.0324320.ref003) 2013; 8
C Stahlhut (pone.0324320.ref010) 2013; 5
MM Gabra (pone.0324320.ref011) 2017; 7
R Garzon (pone.0324320.ref021) 2008; 111
I De Kouchkovsky (pone.0324320.ref001) 2016; 6
M Wass (pone.0324320.ref008) 2016; 11
AJ Favreau (pone.0324320.ref020) 2016; 5
R Ciftciler (pone.0324320.ref012) 2019; 19
L-H Xu (pone.0324320.ref017) 2015; 19
DA Arber (pone.0324320.ref004) 2016; 127
K Mrózek (pone.0324320.ref006) 2008; 35
N Maksimovic (pone.0324320.ref002) 2018; 54
K Mrózek (pone.0324320.ref005) 2004; 18
RA Boon (pone.0324320.ref015) 2013; 495
NS Bhise (pone.0324320.ref019) 2019; 10
NS Bhise (pone.0324320.ref013) 2015; 6
References_xml – volume: 43
  start-page: 884
  issue: 6
  year: 2015
  ident: pone.0324320.ref014
  article-title: Inflammation-associated microRNA-130b down-regulates cytochrome P450 activities and directly targets CYP2C9
  publication-title: Drug Metab Dispos
  doi: 10.1124/dmd.114.062844
– volume: 127
  start-page: 2391
  issue: 20
  year: 2016
  ident: pone.0324320.ref004
  article-title: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
  publication-title: Blood
  doi: 10.1182/blood-2016-03-643544
– volume: 5
  start-page: 4
  year: 2016
  ident: pone.0324320.ref020
  article-title: miR-199b, a novel tumor suppressor miRNA in acute myeloid leukemia with prognostic implications
  publication-title: Exp Hematol Oncol
  doi: 10.1186/s40164-016-0033-6
– volume: 66
  year: 2020
  ident: pone.0324320.ref018
  article-title: Diagnostic value of mir-34a in bone marrow mononuclear cells of acute myeloid leukemia patients
  publication-title: Clin Lab
– volume: 8
  start-page: 14
  issue: 1
  year: 2013
  ident: pone.0324320.ref003
  article-title: Work-related leukemia: a systematic review
  publication-title: J Occup Med Toxicol
  doi: 10.1186/1745-6673-8-14
– volume: 10
  start-page: 319
  issue: 4
  year: 2019
  ident: pone.0324320.ref019
  article-title: MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia
  publication-title: Genes (Basel)
  doi: 10.3390/genes10040319
– volume: 111
  start-page: 3183
  issue: 6
  year: 2008
  ident: pone.0324320.ref021
  article-title: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia
  publication-title: Blood
  doi: 10.1182/blood-2007-07-098749
– volume: 15
  start-page: 37
  issue: 1
  year: 2016
  ident: pone.0324320.ref009
  article-title: Clinical significance of microRNAs in chronic and acute human leukemia
  publication-title: Mol Cancer
  doi: 10.1186/s12943-016-0518-2
– volume: 19
  start-page: 4841
  issue: 24
  year: 2015
  ident: pone.0324320.ref017
  article-title: Overexpressed miR-155 is associated with initial presentation and poor outcome in Chinese pediatric acute myeloid leukemia
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 6
  issue: 7
  year: 2016
  ident: pone.0324320.ref001
  article-title: Acute myeloid leukemia: a comprehensive review and 2016 update
  publication-title: Blood Cancer J
  doi: 10.1038/bcj.2016.50
– volume: 9
  start-page: 76
  year: 2014
  ident: pone.0324320.ref016
  article-title: Prognostic value of miR-96 in patients with acute myeloid leukemia
  publication-title: Diagn Pathol
  doi: 10.1186/1746-1596-9-76
– volume: 7
  start-page: 255
  year: 2017
  ident: pone.0324320.ref011
  article-title: microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview
  publication-title: Front Oncol
  doi: 10.3389/fonc.2017.00255
– volume: 19
  start-page: 729
  year: 2019
  ident: pone.0324320.ref012
  article-title: Impact of time between induction chemotherapy and complete remission on survival outcomes in patients with acute myeloid leukemia
  publication-title: Clin Lymphoma Myeloma Leuk
  doi: 10.1016/j.clml.2019.08.007
– volume: 18
  start-page: 115
  issue: 2
  year: 2004
  ident: pone.0324320.ref005
  article-title: Cytogenetics in acute leukemia
  publication-title: Blood Rev
  doi: 10.1016/S0268-960X(03)00040-7
– volume: 6
  start-page: 324
  year: 2015
  ident: pone.0324320.ref013
  article-title: MicroRNA-mRNA Pairs Associated with outcome in AML: From in vitro cell-based studies to AML patients
  publication-title: Front Pharmacol
– volume: 35
  start-page: 365
  year: 2008
  ident: pone.0324320.ref006
  article-title: Acute myeloid leukemia with a complex karyotype
  publication-title: Semin Oncol
  doi: 10.1053/j.seminoncol.2008.04.007
– volume: 140
  start-page: 1345
  issue: 12
  year: 2022
  ident: pone.0324320.ref007
  article-title: Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel on behalf of the ELN
  publication-title: Blood
  doi: 10.1182/blood.2022016867
– volume: 11
  issue: 10
  year: 2016
  ident: pone.0324320.ref008
  article-title: Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0164587
– volume: 5
  start-page: 111
  issue: 12
  year: 2013
  ident: pone.0324320.ref010
  article-title: MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications
  publication-title: Genome Med
  doi: 10.1186/gm516
– volume: 54
  year: 2018
  ident: pone.0324320.ref002
  article-title: Incidence and Mortality Patterns of Acute Myeloid Leukemia in Belgrade, Serbia (1999–2013)
  publication-title: Medicina (Kaunas)
– volume: 495
  start-page: 107
  issue: 7439
  year: 2013
  ident: pone.0324320.ref015
  article-title: MicroRNA-34a regulates cardiac ageing and function
  publication-title: Nature
  doi: 10.1038/nature11919
SSID ssj0053866
Score 2.478529
Snippet Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are independent...
Background Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are...
BackgroundAcute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are...
Background Acute myeloid leukemia (AML) is associated with the accumulation of acquired genetic disorders. Moreorver chromosomal and molecular changes are...
SourceID plos
doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage e0324320
SubjectTerms Acute myeloid leukemia
Adult
Aged
Analysis
Antimetabolites, Antineoplastic - therapeutic use
Biology and life sciences
Bone marrow
Chemotherapy
Chromosomes
Cytarabine
Cytarabine - therapeutic use
Disease
Epigenetics
Female
fms-Like Tyrosine Kinase 3 - genetics
Gene Expression Regulation, Leukemic - drug effects
Genes
Genetic disorders
Health aspects
Humans
Induction Chemotherapy
Induction therapy
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemogenesis
Male
Medical prognosis
Medicine and Health Sciences
MicroRNA
MicroRNAs
MicroRNAs - genetics
MicroRNAs - metabolism
Middle Aged
miRNA
Morphology
Mutation
Nucleophosmin
Oncology
Patients
Pilot Projects
Prognosis
Remission (Medicine)
Risk factors
Statistical analysis
Stem cell transplantation
Testing
Treatment Outcome
Variables
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtNAEF6hnrggyl8DBQaEBBzc2t4f28eCqAoSPyoU9Wat17vFIrGj2JHIjXfgQXgnnoQZexPFqBIcuHonlj0zO_uNM_MNY0_iGGGyKWQgeKEC4UoX6EInQVkqXmS8zHQ_bOLtO3VyJt6cy_OtUV9UEzbQAw-KO-QIiLNIyMw5IWh6lVI2dJLrSLiiTPrWPTzz1snUEINxFyvlG-V4Eh16uxzMm9oehIghOM333jqIer7-TVTemU-b9jLI-Wfl5NZRdHydXfMYEo6GZ99lV2x9g-36XdrCM08l_fwm-_lhYTel5GC_-arXGhoHs-o0wDRKw0yvABfKynSwGEpmLXQNIDQEzNgHellA4858t9YK6Owrga6uOr3QmF2TKGiz7CzMVnbaVCVM7fKrnVUaPHdrC7--_wAN9HViagN6ObuAeTVtMAGAnuf2Fjs7fvXp5UngRzQEBoFUFyjhIu0UT6QJCzR5IVG32hkTpWVSqiI1SWhcJrUMrYltWpAhQ5u4wshMupjfZjs1GmWPgTWpLpRyseRCZET7J8MyiWNtuXNWRRMWrO2Vzwcmjrz_Oy7BDGZQfE72zb19J-wFGXUjSzza_QX0rtx7V_4375qwh-QS-dCUuokG-VEqqH5IKD5hj3sJ4tKoqVjnQi_bNn_9_vM_CH08HQk99UKuQecy2jdI4DsRR9dIcn8kiRHBjJb3yIHXWmlzDNq0ITAZxl-unfry5UebZbopFeDVtlkOMhkl56jXO8Me2GgWMT_icCkmLB3tjpHqxyt19aWnMo9oJBpC5rv_w1j32NWYpjOHKojFPtvpFkt7HyFjVzzoo8NvvYlunw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lj5RAEO7oePFiXF87umprTNQDu0A_gJNZjeNq4iOra_ZGmqZ7lzgDIzCJc_M_-EP8T_4Sq6AHF7MxXqmCQL26qqn-ipBHYQhpss6Ex1kmPW5z66lMRV6eS5YlLE9UN2zi7Tt5cMTfHItjt-HWuLbKTUzsAnVeadwj3wPDYzEuJsmz5VcPp0bh31U3QuMiuRTASoMtXfHs1SYSC7zBHZdjUbDntLO7rEqz60MmwXDK95nlqEPtH2LzZDmvmvMSz7_7J88sSLOr5IrLJOl-r_otcsGU18iW89WGPnGA0k-vk58fajM0lFPzzfW-lrSydFEcelBMKbpQawqEvNAtrfvGWUPbikKCSKFu70FmKah44c5srSmugDnFq-tW1QpqbGSlSq9aQxdrM6-KnM7N6otZFIo6BNeG_vr-gyqKexRz4-HHmZoui3kFZQDt0G5vkKPZy08vDjw3qMHTkE61nuQ2UFaySGg_A8VnAmSrrNZBnEe5zGId-domQgnf6NDEGReJ9U1kMy0SYUN2k0xKUMo2oUbHKpPShoJxniD4n_DzKAyVYdYaGUyJt9FXuuzxONLup1wEdUwv-BT1mzr9TslzVOrAi2ja3YWqPkmdc6YMiq4kwJeynOOENCmNbwVTAbdZHiVTch9NIu2Ppg4xId2POXYRccmm5GHHgYgaJbbsnKhV06Sv33_-D6aPhyOmx47JVmBcWrljEvBNiNQ14twZcUJc0CPyNhrwRipN-seD4M6NUZ9PfjCQ8aHYhleaatXzJFiig1xv9T4wSBYyf8jGBZ-SeOQdI9GPKWVx2gGaBzgYDRLn2_9-rzvkcojTl33phXyHTNp6Ze5CSthm9zq__w0c4WZN
  priority: 102
  providerName: ProQuest
Title Pretreatment expression of miR-191a may predict response to the induction chemotherapy based on cytarabine in acute myeloid leukemia patients – a single-center pilotal study
URI https://www.ncbi.nlm.nih.gov/pubmed/40554554
https://www.proquest.com/docview/3223866149
https://www.proquest.com/docview/3223928990
https://pubmed.ncbi.nlm.nih.gov/PMC12186893
https://doaj.org/article/357691459ff44ce2a66e0f53a14fbd79
http://dx.doi.org/10.1371/journal.pone.0324320
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELbK9sIFUV5dKItBSMDBVR62kxwQaquWgtRSFYp6ixzHLit2kyXJSt0fxX9kJvFGBBWplxziSZTMyzP2-BtCXgcBhMk6E4yHmWTc5papTEUsz2WYJWGeqLbZxMmpPL7gny_F5QZZ92x1DKxvTO2wn9RFNdu9_rX6AAb_vu3aEPnrh3YXZWF2PYgQwgCS-E2YmyLsaXDC-30FsO529xKjFiYDL3SH6f73lsFk1WL69557tJiV9U1h6b_VlX9NV0f3yT0XZ9K9TjG2yIYpHpAtZ8k1fevgpt89JL_PKtOXm1Nz7SpjC1paOp-eM0i1FJ2rFYWBfKobWnVltYY2JYXwkUJW30HQUlCAuTvRtaI4P-YU764aVSnIwJGUKr1sDJ2vzKyc5nRmlj_NfKqow3etKaOK4vrFzDD8NVPRxXRWgnRoi4T7iFwcHX47OGauiQPTEGo1THLrKyvDSGgvA6XIBHBWWa39OI9ymcU68rRNhBKe0YGJMy4S65nIZlokwgbhYzIqQCTbhBodq0xKG4iQ8wSBAYWXR0GgTGitkf6YsLW00kWH1ZG2G3YR5Dgd21OUbuqkOyb7KNKeFpG22xtldZU6w01DSMgSHz_Kco7d06Q0nhWh8rnN8igZkxeoEGl3bLX3F-lezLHCiMtwTF61FIi2UWA5z5Va1nX66cv3WxB9PR8QvXFEtgTV0sodoYB_QhSvAeXOgBJ8hh4Mb6P6rrlSp-DW0TQgXYYn1yp98_DLfhhfiiV6hSmXHU2C6Tvw9UlnAT1nISuASF3wMYkHtjFg_XCkmP5owc59bJoGQfXT23DxGbkbYH9mT7KA75BRUy3Ncwgam2xC7kSXEVzjAx-vRx8nZHP_8PTsfNIuw0xaP_EHmJ5zUQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JbtRAEG1F4QAXRFgHAmkQCDg4sd3dXg4IhSUkZAGFBOVm2r0Eixl7GHsEc-Mf-A_4J76EKi9DjCLEJVd3zahdVV1Lu-oVIfd9H8JklQqHszRwuNXWkakMHa0DlsZMx7IeNrG7F2we8tdH4miB_Oh6YbCssrOJtaHWhcI78jVQPBahM4mfjj87ODUKv652IzQatdg2sy-QspVPtl6AfB_4_sbLg-ebTjtVwFHg-ysn4NaTNmChUG4Ku0yFz5m0SnmRDnWQRip0lY2FFK5RvolSLmLrmtCmSsTCItABmPxznIEnx870jVed5Re4wbY9j4XeWqsNq-MiN6suRC4Mp4qfcH_1lIC5L1gcD4vytED373rNEw5w4xK52EaudL1RtSWyYPLLZKm1DSV91AJYP75Cfr6dmHkBOzVf21rbnBaWjrJ9B5I3SUdyRmFBZ6qik6ZQ19CqoBCQ0izXDagtBZUatT1iM4oeV1N8OqvkREJOj6RUqmll6GhmhkWm6dBMP5lRJmmLGFvSX9--U0nxTmRoHHw5M6HjbFhA2kFrdN2r5PBMRHiNLOYglBuEGhXJNAisLxjnMYINCleHvi8Ns9YE3oA4nbyScYP_kdQfAUPImxrGJyjfpJXvgDxDoc5pEb27flBMjpPWGCQMkrzYw01ZznEiWxAY1womPW5THcYDsoIqkTStsHMblKxHHKuWeMAG5F5NgQgeOZYIHctpWSZbb97_B9G7_R7Rw5bIFqBcSrZtGfBOiAzWo1zuUYIdUr3lG6jAHVfK5M-JhV92Sn368t35Mv4plv3lppg2NDFeCQBfrzdnYM5ZyDQg-hd8QKLe6eixvr-SZx9rAHUPB7FBoH7z3_taIec3D3Z3kp2tve1b5IKPk5_dwPH5MlmsJlNzG8LRKr1T2wBKPpy10fkNunmk6Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELaqIiEuiPLXhUINAgGHtEls5-eAUGmpWgqlKhT1FhzHLhG7ybLJCvbGO_Ag3HkcnoSZxBsaVCEuvWZmV87MeH6c8TeEPPB9SJNVKhzO0sDhJjOOTGXoZFnA0phlsWyGTbzeD3aO-MtjcbxAfs7vwmBb5dwnNo46KxWeka-D4bEIg0m8bmxbxMHW9rPxZwcnSOGX1vk4jdZE9vTsC5Rv1dPdLdD1Q9_ffvFuc8exEwYcBXlA7QTceNIELBTKTWHFqfA5k0YpL8rCLEgjFbrKxEIKVytfRykXsXF1aFIlYmEQ9ADc_4WQhRHusWizay8RuFh7VY-F3rq1jLVxWeg1F7IYhhPGT4XCZmJAFxcWx8OyOivp_bt381Qw3L5CLtsslm60ZrdEFnRxlSxZP1HRxxbM-sk18uNgortmdqq_2r7bgpaGjvJDBwo5SUdyRoGQ5aqmk7ZpV9O6pJCc0rzIWoBbCuY1svfFZhSjb0bx6ayWEwn1PbJSqaa1pqOZHpZ5Rod6-kmPckktemxFf337TiXF85GhdvDl9ISO82EJJQhtkHavk6NzUeENsliAUpYJ1SqSaRAYXzDOYwQeFG4W-r7UzBgdeAPizPWVjFsskKT5IBhCDdUKPkH9Jla_A_IcldrxIpJ386CcnCTWMSQMCr7Yw0UZznE6WxBo1wgmPW7SLIwHZBVNImmvxXb-KNmIOHYw8YANyP2GA9E8CtwXJ3JaVcnum_f_wfT2sMf0yDKZEoxLSXtFA94JUcJ6nCs9TvBJqkdeRgOeS6VK_uxe-OXcqM8m3-vI-KfYAljoctryxHg8AHK92e6BTrJQdUAlIPiARL3d0RN9n1LkHxswdQ-HskHSfuvf61olF8HdJK929_duk0s-DoF2A8fnK2Sxnkz1HchM6_Ru4wIo-XDePuc3o_6o6g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pretreatment+expression+of+miR-191a+may+predict+response+to+the+induction+chemotherapy+based+on+cytarabine+in+acute+myeloid+leukemia+patients+-+a+single-center+pilotal+study&rft.jtitle=PloS+one&rft.au=Szymczyk%2C+Agnieszka&rft.au=Chocholska%2C+Sylwia&rft.au=Radko%2C+Katarzyna&rft.au=Hus%2C+Marek&rft.date=2025-06-24&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=20&rft.issue=6&rft.spage=e0324320&rft_id=info:doi/10.1371%2Fjournal.pone.0324320&rft.externalDBID=IOV&rft.externalDocID=A845209463
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon